UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Earliest Event Reported: March 31, 2011
ImmunoCellular Therapeutics, Ltd.
(Exact name of registrant as specified in its charter)
| Delaware | 33-17264-NY | 11-2856146 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 1999 Avenue of the Stars, 11th Floor Los Angeles, California |
90067 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (310) 423-0845
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 31, 2011, as a result of the expiration of the term of the Agreement dated as of October 30, 2010 between C. Kirk Peacock and ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), the employment of Mr. Peacock as the Company’s Treasurer and Chief Financial Officer terminated.
Effective April 4, 2011, David Fractor, age 51, became the Company’s Treasurer and Chief Financial Officer. Mr. Fractor will serve in this capacity on a part-time basis for a three-year term, subject to termination by either party on 30 days notice. Under this agreement, Mr. Fractor receives a monthly salary of $6,000 and was granted a seven-year option to purchase 42,000 shares of the Company’s common stock at a price of $2.25 per share, with such option to vest in equal monthly installments over the three-year term of the agreement. For the past eight years, Mr. Fractor has been a sole practitioner involving accounting and financial reporting for various firms and previously was Chief Financial Officer for Hemacare Corporation, a company which provides blood products to patients and hospitals.
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ImmunoCellular Therapeutics, Ltd. | ||||||
| April 6, 2011 | By: | /s/ Manish Singh | ||||
| Name: | Manish Singh, Ph.D. | |||||
| Title: | President and Chief Executive Officer | |||||
- 3 -